Back to NewEdge Advisors, LLC NewEdge Advisors, LLC

BLRXBLRX
6 quarters

Position history for NewEdge Advisors, LLCNewEdge Advisors, LLC's holdings in BIOLINE RX LIMITED

Yes. Newedge Group holds 82 shares of BLRX (Bioline RX), worth $256, as of its Q2 2026 13F filing. It reduced the position by 25 shares (-23.4%) from Q1 2026. Newedge Group has held BLRX since Q1 2025, across 6 quarterly 13F filings.

Current Value

$256

Current Shares

82

Total Value Change

-$61

Total Shares Change

-25

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
82
-23.4%
$2560.0%$3.12
0
2026-Q1
Unchanged
107
0.0%
$2470.0%$2.81
0
2025-Q4
Unchanged
107
0.0%
$2960.0%$2.87
0
2025-Q3
Unchanged
107
0.0%
$4050.0%$3.76
0
2025-Q2
Unchanged
107
0.0%
$4890.0%$4.43
0
2025-Q1
New
107
-
$3170.0%$3.05
17

Other major holders of BLRX: CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, SIMPLEX TRADING, LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used